In Vitro and In Vivo Characterization of a Novel Nonsteroidal, Species-Specific Progesterone Receptor Modulator, PRA-910
The progesterone receptor (PR) is an important regulator of female reproduction. Consequently, PR modulators have found numerous pharmaceutical utilities in women's reproductive health. In the process of identifying more receptor-specific and tissue-selective PR modulators, we discovered a novel nonsteroidal, 6-aryl benzoxazinone compound, PRA-910, that displays unique in vitro and in vivo activities. In a PR/PRE reporter assay in COS-7 cells, PRA-910 shows potent PR antagonist activity with an IC50 value of approximately 20 nM. In the alkaline phosphatase assay in the human breast cancer cell line T47D, PRA-910 is a partial progesterone antagonist at low concentrations and is also an effective PR agonist at higher concentrations (EC50 value of approximately 700 nM). PRA-910 binds to the human PR with high affinity (K d=4 nM) and was previously shown to exhibit greater than 100-fold selectivity for the PR versus other steroid receptors. In the adult ovariectomized rat, PRA-910 is a potent PR antagonist. It inhibits progesterone-induced uterine decidual response with an ED50 value of 0.4 mg/kg, p.o., and reverses progesterone suppression of estradiol-induced complement C3 expression with potency similar to RU-486. In the nonhuman primate, however, PRA-910 is a PR agonist. The effect on endometrial histology strongly resembles that of progesterone. This unique compound also suppresses estradiol-induced epithelial cell proliferation and both estrogen and progesterone receptor expression in the uterine endometrium as a PR agonist would. In summary, PRA-910 is a structurally and biologically novel selective PR modulator with either PR agonist or antagonist activity, depending on context, concentration, and species.
KeywordsProgesterone Receptor T47D Cell Testosterone Propionate Postmenopausal Hormone Therapy Alkaline Phosphatase Assay
The authors wish to thank Dr. S.G. Lundeen for numerous contributions to this project. Dr. O. Slayden is a recipient of grant #RR00163 from Oregon National Primate Center.
- Foidart JM (2000) The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects. Eur J Contracept Reprod Health Care 5 [Suppl 3]:25–33Google Scholar
- Tabata Y, Iizuka Y, Shinei R, i Kurihara K, Okonogi T, Hoshiko S, Kurata Y (2003) CP8668, a novel orally active nonsteroidal progesterone receptor modulator with tetrahydrobenzindolone skeleton. [erratum appears in Eur J Pharmacol 2003 Apr 4;465(3):299]. Eur J Pharmacol 461:73–78PubMedCrossRefGoogle Scholar
- Zhang Z, Funk C, Glasser SR, Mulholland J (1994) Progesterone regulation of heparin-binding epidermal growth factor-like growth factor gene expression during sensitization and decidualization in the rat uterus: effects of the antiprogestin, ZK 98.299. Endocrinology 135:1256–1263PubMedCrossRefGoogle Scholar